JDP2 and neoplasm: We have shown that JDP2 is preferentially up-regulated in ETP-ALL (Fig. 1, C and D), and support for increased GC resistance in human ETP-ALL is provided by recent studies in human T-ALL patient-derived tumor graft models, in which Delgado-Martin et al. (2017) demonstrated that cells from ETP T-ALL models are intrinsically more resistant to GCs than are cells from non-ETP T-ALLs.